TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02472171

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, blueberry powder and sunflower oil
Description: High saturated fat meal with blueberry powder shake and sunflower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, blueberry powder and sunflower oil
Description: High saturated fat meal with blueberry powder shake and sunflower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, blueberry powder and sunflower oil
Description: High saturated fat meal with blueberry powder shake and sunflower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, blueberry powder and sunflower oil
Description: High saturated fat meal with blueberry powder shake and sunflower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, placebo powder and DHA
Description: High saturated fat meal with a blueberry flavored shake and DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, placebo powder and DHA
Description: High saturated fat meal with a blueberry flavored shake and DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, placebo powder and DHA
Description: High saturated fat meal with a blueberry flavored shake and DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, placebo powder and DHA
Description: High saturated fat meal with a blueberry flavored shake and DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, placebo powder and DHA
Description: High saturated fat meal with a blueberry flavored shake and DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High saturated fat meal, placebo powder and DHA
Description: High saturated fat meal with a blueberry flavored shake and DHA
Study: NCT02254161

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181 healthy elderly
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1181181 Healthy young
Description: Tablet
Study: NCT01452711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
Study: NCT01616277

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-06252616
Description: 10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose
Study: NCT02737527

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temperature measurement for Lumbar Sympathetic Block (LSB)
Description: Temperature monitoring and measurement: skin-surface temperatures are monitored with small, adhesive thermocouple probes attached bilaterally to the plantar surface of the feet using transparent patches at 1-min intervals for a maximum of 20 min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postprocedure care for LSB
Description: Adverse events such as genitofemoral nerve block, lumbar plexus block (transient unilateral leg weakness), or others are documented during and after the procedure for 30 min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postprocedure care for LSB
Description: Adverse events such as genitofemoral nerve block, lumbar plexus block (transient unilateral leg weakness), or others are documented during and after the procedure for 30 min.
Study: NCT01616277

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06252616, IV infusion, repeat dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-06252616
Description: 20.0 milligram per kilogram of PF-06252616, IV infusion, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06252616, IV infusion, single dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PF-06252616
Description: 40.0 milligram per kilogram of PF-06252616, IV infusion, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06252616, IV infusion, single dose
Study: NCT02804490

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Conventional white maize
Description: Women and their infants will receive 2 meals/day prepared with conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Provitamin A carotenoid biofortified maize
Description: Women and their infants will receive 2 meals/day prepared with provitamin A carotenoid biofortified orange maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Preformed vitamin A fortified maize
Description: Women and their infants will receive 2 meals/day prepared with preformed vitamin A fortified, conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
Study: NCT03531814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS^TM)
Description: A computerized method of tracking the dates and times of a pill bottle being opened.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS^TM)
Description: A computerized method of tracking the dates and times of a pill bottle being opened.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Adult and pediatric participants completed a series of questionnaires to assess medication adherence, demographics, life events, and barriers to adherence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Adult and pediatric participants completed a series of questionnaires to assess medication adherence, demographics, life events, and barriers to adherence.
Study: NCT01849315

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AKIDS II
Description: Physically active intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: AKIDS II
Description: Physically active intervention
Study: NCT03375931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prayer
Description: If the patient wishes to pray, the anesthesiologist will pray for one minute before anesthesia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: non-prayer
Description: If the patient does not want to pray, the anesthesiologist does anesthesia without praying.
Study: NCT01913847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Oral sildenafil 20 mg TID for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo TID for 12 weeks
Study: NCT01673646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: Intramuscular administration of pasireotide LAR was repeated every month (1 month = 28 days) for 12 months in core phase. It was permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels ≥2.5 µg/L and/or IGF-1 \> ULN. In the event of any problem with tolerability, it was permitted to reduce the next lower dosage level at any time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: Intramuscular administration of pasireotide LAR was repeated every month (1 month = 28 days) for 12 months in core phase. It was permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels ≥2.5 µg/L and/or IGF-1 \> ULN. In the event of any problem with tolerability, it was permitted to reduce the next lower dosage level at any time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: Intramuscular administration of pasireotide LAR was repeated every month (1 month = 28 days) for 12 months in core phase. It was permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels ≥2.5 µg/L and/or IGF-1 \> ULN. In the event of any problem with tolerability, it was permitted to reduce the next lower dosage level at any time.
Study: NCT01485796

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Infusion (Human), 10%
Description: Subcutaneous administration will be used in Study Epochs 1 and 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human hyaluronidase
Description: rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.
Study: NCT00845481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivobet® ointment
Description: Once daily application 6 days a week for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betnovat® ointment
Description: Once daily application 6 days a week for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diprosalic ointment
Description: Once daily application 6 days a week for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermovat ointment
Description: Once daily application 6 days a week for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elocon ointment
Description: Once daily application 6 days a week for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivobet® ointment vehicle
Description: Once daily application 6 days a week for 3 weeks
Study: NCT01514149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJC-1134-PC Injection
Description: CJC-1134-PC administered weekly by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJC-1134-PC Injection
Description: CJC-1134-PC administered weekly by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJC-1134-PC Injection
Description: CJC-1134-PC administered weekly by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Weekly placebo for CJC-1134-PC Injection
Description: Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection
Study: NCT02252042

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenous (IV) on Day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 40 mg/m\^2 IV (may be escalated to 60 mg/m\^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m\^2 IV on Day 1 of each 3- week cycle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400 mg/m\^2 IV loading dose on Day 1 and 250 mg/m\^2 IV on Days 8 and 15 of Cycle 1, followed by 250 mg/m\^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
Study: NCT02168400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS will be performed with Neuroelectrics Starstim Enobio 20, a non-invasive investigational device that has been labeled as a non-significant risk device by the FDA. This study is regulated by the FDA as an Abbreviated IDE. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
Study: NCT04456751

Intervention type: OTHER
Intervention: Redo op
Description: Patients with a redo operation
Study: NCT03926039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sharing decision-making program
Description: Sharing decision-making talks and decision-making assistance tools used in the process
Study: NCT04226625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Volatile administration
Study: NCT01722994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyglactin 910 sterile synthetic absorbable suture (Ethicon)
Description: Half of punch biopsy wounds are closed with each absorbablesuture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chromic Gut Sterile absorbable Suture (Ethicon)
Study: NCT02440139

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClearRead CT Insight
Description: During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed and the vessel suppressed same slice with the vessel suppressed view as the intervention. The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).
Study: NCT00640250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
Description: Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours.
Study: NCT02722473

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NSE dosage hypothermia arm
Description: There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management between 33° and 37°C.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: NSE dosage normothermia arm
Description: There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management at 37°C.
Study: NCT02869334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial direct current stimulation (tDCS)
Description: Active tDCS, where an extremely weak electric current passes through the brain

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Transcranial direct current stimulation (tDCS)
Description: Sham (inactive or placebo) tDCS
Study: NCT00158756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™-HepB
Description: GSK Biologicals' combined diphtheria-tetanus-whole cell Bordetella pertussis -hepatitis B vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™-HepB
Description: GSK Biologicals' combined diphtheria-tetanus-whole cell Bordetella pertussis -hepatitis B vaccine.
Study: NCT01949298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant placement
Study: NCT00158756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: GSK Biologicals' live attenuated human rotavirus vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix™
Description: GSK Biologicals' live attenuated human rotavirus vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zilbrix™
Description: GSK Biologicals Kft's combined diphtheria-tetanus whole-cell B. pertussis-hepatitis B vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zilbrix™
Description: GSK Biologicals Kft's combined diphtheria-tetanus whole-cell B. pertussis-hepatitis B vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Triple Antigen™
Description: Commonwealth Serum Laboratory's (CSL's) combined diphtheria-tetanus-whole cell B. pertussis vaccine.
Study: NCT00924001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMF5 Melanoma Reactive TIL
Description: given intravenously over 20-30 minutes (between 1 x 10\^9 and 1 x 10\^11 lymphocytes) after expansion in interleukin-2 and OKT-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/day x 2 days intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenously x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 720,000 IU/kg/dose intravenously every 8 hours for up to 15 doses
Study: NCT01580410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitomycin C
Description: Given by HIPEC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given by HIPEC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study: NCT00158756

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: GSK Biologicals' hepatitis B vaccine
Study: NCT01580410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperthermic intraperitoneal chemotherapy
Description: Undergo HIPEC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperthermic intraperitoneal chemotherapy
Description: Undergo HIPEC
Study: NCT03706027

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy-3 fractions
Description: Radiation therapy given in a 3 fraction schedule (over 3 days). Total dose is 54 Grays.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy-5 fractions
Description: Radiation therapy given in 5 fractions (over 5 days). Total dose is 60 Grays.
Study: NCT01194245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human hyaluronidase PH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human hyaluronidase PH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Study: NCT03162133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Study: NCT03611998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupation-based programming
Description: Group sessions consisted of specific tasks performed to completion that emphasized skills such as problem-solving, decision-making, frustration tolerance, appropriate pacing, attention, inquiring, sequencing, gathering, organizing, adjusting, responding, enduring, initiating and cooperating. Examples of tasks included projects that the women were specifically interested in learning such as jewelry making, holiday decorations, clay work and other home décor projects. Investigators observed these and other behaviors during the group sessions, and scored individuals using the OTTOS instrument.
Study: NCT03707158

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-led Face-to-Face Cognitive-Behavioral Therapy
Description: Participants receiving face-to-face cognitive-behavioral therapy will participate in therapist-led, office-based or telehealth CBT treatment for up to 16 weeks. Sessions focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Cognitive-Behavioral Therapy
Description: Participants receiving digital cognitive-behavioral therapy will complete an online, largely self-administered CBT program for up to 16 weeks with 8 modules and adjunctive therapist phone support. Treatment modules focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.